{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:30:55Z","timestamp":1795102255334,"version":"4.10.3"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>This double-blind, randomized, placebo-controlled, parallel-group study evaluated efficacy and safety of elagolix in cohorts 1 (300 mg twice daily) and 2 (600 mg daily) with four arms per cohort: placebo, elagolix alone, elagolix with 0.5 mg estradiol\/0.1 norethindrone acetate, and elagolix with 1.0 mg estradiol\/0.5 mg norethindrone acetate. A sample size of 65 per group was planned to compare elagolix with add-back to placebo on the primary end point: the percentage of women who had less than 80 mL menstrual blood loss and 50% or greater reduction in menstrual blood loss from baseline to the last 28 days of treatment. Safety assessments included changes in bone mineral density.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      From April 8, 2013, to December 8, 2015, 571 women were enrolled, 567 were randomized and treated (cohort 1=259; cohort 2=308), and 80% and 75% completed treatment, respectively. Participants had a mean\u00b1SD age of 43\u00b15 years (cohort 2, 42\u00b15 years), and 70% were black (cohort 2, 74%). Primary end point responder rates in cohort 1 (cohort 2) were 92% (90%) for elagolix alone, 85% (73%) for elagolix with 0.5 mg estradiol\/0.1 mg norethindrone acetate, 79% (82%) for elagolix with 1.0 mg estradiol\/0.5 mg norethindrone acetate, and 27% (32%) for placebo (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.001 vs placebo). Elagolix groups had significant decreases compared with placebo in lumbar spine bone mineral density, which was attenuated by adding 1.0 mg estradiol\/0.5 mg norethindrone acetate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Elagolix with and without add-back significantly reduced menstrual blood loss in women with uterine leiomyomas. Add-back therapy reduced hypoestrogenic effects on bone mineral density.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT01817530; EU Clinical Trial Register, 2013-000082-37.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000002933","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T21:04:56Z","timestamp":1539119096000},"page":"1252-1264","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":68,"title":["Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas"],"prefix":"10.1097","volume":"132","author":[{"given":"Bruce R.","family":"Carr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Al-Hendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte D.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristof","family":"Chwalisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Rachel","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Dufek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261028","doi-asserted-by":"crossref","first-page":"16043","DOI":"10.1038\/nrdp.2016.43","article-title":"Uterine fibroids","volume":"2","author":"Stewart","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20261028","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R3-20261028","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.fertnstert.2006.05.047","article-title":"Characterization of estrogen receptors alpha and beta in uterine leiomyoma cells","volume":"86","author":"Valladares","year":"2006","journal-title":"Fertil Steril"},{"key":"R4-20261028","doi-asserted-by":"crossref","first-page":"1010428317710226","DOI":"10.1177\/1010428317710226","article-title":"Molecular and clinical attributes of uterine leiomyomas","volume":"39","author":"Dvorsk\u00e1","year":"2017","journal-title":"Tumour Biol"},{"key":"R5-20261028","first-page":"1217","article-title":"An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial","volume":"76","author":"Carr","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-20261028","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000114250","article-title":"Relationship between metabolic syndrome and uterine leiomyomas: a case-control study","volume":"66","author":"Takeda","year":"2008","journal-title":"Gynecol Obstet Invest"},{"key":"R7-20261028","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/1471-0528.14640","article-title":"Epidemiology of uterine fibroids: a systematic review","volume":"124","author":"Stewart","year":"2017","journal-title":"BJOG"},{"key":"R8-20261028","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2017.09.004","article-title":"Epidemiology and risk factors of uterine fibroids","volume":"46","author":"Pavone","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R9-20261028","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1055\/s-0037-1607264","article-title":"Uterine fibroids: burden and unmet medical need","volume":"35","author":"Al-Hendy","year":"2017","journal-title":"Semin Reprod Med"},{"key":"R10-20261028","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2010.11.011","article-title":"FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age","volume":"113","author":"Munro","year":"2011","journal-title":"Int J Gynaecol"},{"key":"R11-20261028","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10815-012-9784-0","article-title":"Leiomyoma: genetics, assisted reproduction, pregnancy and therapeutic advances","volume":"29","author":"Levy","year":"2012","journal-title":"J Assist Reprod Genet"},{"key":"R12-20261028","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1089\/jwh.2013.4334","article-title":"The burden of uterine fibroids for African-American women: results of a national survey","volume":"22","author":"Stewart","year":"2013","journal-title":"J Womens Health (Larchmt)"},{"key":"R13-20261028","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejogrb.2010.05.012","article-title":"The burden of uterine fibroids in five European countries","volume":"152","author":"Downes","year":"2010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R14-20261028","doi-asserted-by":"crossref","first-page":"319.e1","DOI":"10.1016\/j.ajog.2013.07.017","article-title":"The impact of uterine leiomyomas: a national survey of affected women","volume":"209","author":"Borah","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"R15-20261028","first-page":"CR24","article-title":"Hysterectomy surveillance in the United States, 1997 through 2005","volume":"14","author":"Merrill","year":"2008","journal-title":"Med Sci Monit"},{"key":"R16-20261028","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humupd\/dmw023","article-title":"Uterine fibroid management: from the present to the future","volume":"22","author":"Donnez","year":"2016","journal-title":"Hum Reprod Update"},{"key":"R17-20261028","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.fertnstert.2017.05.006","article-title":"Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study","volume":"108","author":"Archer","year":"2017","journal-title":"Fertil Steril"},{"key":"R18-20261028","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1210\/jc.2016-3845","article-title":"Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women","volume":"102","author":"Ng","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-20261028","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1210\/jc.2008-1695","article-title":"Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix","volume":"94","author":"Struthers","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-20261028","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/00016346609158455","article-title":"Menstrual blood loss\u2014a population study. Variation at different ages and attempts to define normality","volume":"45","author":"Hallberg","year":"1966","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R22-20261028","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/00365516409060511","article-title":"Determination of menstrual blood loss","volume":"16","author":"Hallberg","year":"1964","journal-title":"Scand J Clin Lab Invest"},{"key":"R23-20261028","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.fertnstert.2011.05.096","article-title":"Validation of a rapid alkaline hematin technique to measure menstrual blood loss on feminine towels containing superabsorbent polymers","volume":"96","author":"Magnay","year":"2011","journal-title":"Fertil Steril"},{"key":"R24-20261028","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/03007995.2016.1248382","article-title":"Validation of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) Questionnaire","volume":"33","author":"Coyne","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"R25-20261028","first-page":"290","article-title":"The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata","volume":"99","author":"Spies","year":"2002","journal-title":"Obstet Gynecol"},{"key":"R26-20261028","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0000000000002675","article-title":"Long-term outcomes of elagolix in women with endometriosis: results from two extension studies","volume":"132","author":"Surrey","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R27-20261028","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1471-0528.1990.tb16249.x","article-title":"Assessment of menstrual blood loss using a pictorial chart","volume":"97","author":"Higham","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"key":"R28-20261028","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.whi.2004.07.005","article-title":"Validating a pencil-and-paper measure of perimenopausal menstrual blood loss","volume":"14","author":"Mansfield","year":"2004","journal-title":"Womens Health Issues"},{"key":"R29-20261028","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1471-0528.2000.tb13225.x","article-title":"Assessment of menstrual blood loss using a pictorial chart: a validation study","volume":"107","author":"Reid","year":"2000","journal-title":"BJOG"},{"key":"R30-20261028","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3109\/13625187.2011.591456","article-title":"Effective treatment of heavy and\/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest","volume":"16","author":"Fraser","year":"2011","journal-title":"Eur J Contracept Reprod Health Care"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006250-201811000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:01:27Z","timestamp":1793203287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006250-201811000-00023"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000002933","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"2018-05-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}